Induced pluripotent stem cells from a spinal muscular atrophy patient
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Spinal muscular atrophy is one of the most common inherited forms of neurological disease leading to infant mortality. Patients have selective loss of lower motor neurons resulting in muscle weakness, paralysis and often death. Although patient fibroblasts have been used extensively to study spinal muscular atrophy, motor neurons have a unique anatomy and physiology which may underlie their vulnerability to the disease process. Here we report the generation of induced pluripotent stem cells from skin fibroblast samples taken from a child with spinal muscular atrophy. These cells expanded robustly in culture, maintained the disease genotype and generated motor neurons that showed selective deficits compared to those derived from the child's unaffected mother. This is the first study to show that human induced pluripotent stem cells can be used to model the specific pathology seen in a genetically inherited disease. As such, it represents a promising resource to study disease mechanisms, screen new drug compounds and develop new therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SMA iPSC-derived motor neurons showed a higher vulnerability with reduced dendritic and axonal length.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Technologies to reprogram adult cells back to a pluripotent state, termed induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006; Yu et al., 2007), provide an unprecedented platform for studying human genetic disorders (Ebert et al., 2009; Mattis et al., 2015).”
From Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier (2017) · cites this paper as Ebert et al., 2009
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“RNA analysis from SMA iPSC-derived motor neuron demonstrates hyperactivation of the endoplasmic reticulum (ER) stress pathway due to activated unfolded SMN [49].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Self-citationBolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
CNS stem cells express a new class of intermediate filament protein
Lendahl, U., Zimmerman, L. B., & McKay, R. D. G. (1990) · Cell · doi:10.1016/0092-8674(90)90662-x · Cited by 3,151
Pvclust: an R package for assessing the uncertainty in hierarchical clustering
Suzuki, R., & Shimodaira, H. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl117 · Cited by 2,451
Reprogramming of human somatic cells to pluripotency with defined factors
Park, I.-H., Zhao, R., West, J. A., Yabuuchi, A., Huo, H., Ince, T. A., Lerou, P. H., Lensch, M. W., & Daley, G. Q. (2008) · Nature · doi:10.1038/nature06534 · Cited by 2,436
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
Neuronal specification in the spinal cord: inductive signals and transcriptional codes
Jessell, T. M. (2000) · Nature Reviews Genetics · doi:10.1038/35049541 · Cited by 2,089
Cited by
Items 701–800 of 1,000
Naujock, M., Stanslowsky, N., Reinhardt, P., Sterneckert, J. L., Haase, A., Martin, U., Kim, K., Dengler, R., Wegner, F., & Petri, S. (2014) · Stem Cells and Development · doi:10.1089/scd.2014.0180 · Cited by 22
“Several recent studies have shown that MNs differentiated from patient-derived iPSCs indeed recapture relevant disease phenotypes comparable to changes in postmortem ALS [5–7] or SMA [8,9] tissue.”
Induced Pluripotent Stem Cells: A New Approach for Physiological Research
Pfannkuche, K., Hannes, T., Khalil, M., Noghabi, M. S., Morshedi, A., Hescheler, J., & Dröge, P. (2010) · Cellular Physiology and Biochemistry · doi:10.1159/000320514 · Cited by 22
Great Expectations: Autism Spectrum Disorder and Induced Pluripotent Stem Cell Technologies
Liu, E. Y., & Scott, C. T. (2014) · Stem Cell Reviews and Reports · doi:10.1007/s12015-014-9497-0 · Cited by 22
“Consequently, iPSC technology has thus far been limited to studies of conditions with known disease phenotypes, such as long-QT syndrome and spinal muscular atrophy [10, 11].”
BackgroundProgramming and reprogramming neuronal subtypes in the central nervous system
Rouaux, C., Bhai, S. F., & Arlotta, P. (2012) · Developmental Neurobiology · doi:10.1002/dneu.22018 · Cited by 20
“This in turn has enabled the first in vitro studies aimed at gaining insight into the pathogenesis of these motor diseases (Di Giorgio et al., 2008; Dimos et al., 2008; Ebert et al., 2009).”
BackgroundMethodInfluentialHuang, H., Chuang, C.-Y., & Kuo, H. (2012) · Stem Cell Research & Therapy · doi:10.1186/scrt125 · Cited by 23
“Th e derivatives of some of these diseasespecifi c iPSCs have been employed as in vitro disease models to test the phenotype-correcting eff ects of small numbers of promising drugs, such as neurons diff erentiated from spinal muscular atrophy-specifi c iPSCs [40] and Rett syndrome-specifi c iPSCs [48] and cardiomyocyt…”
BackgroundCurrent status of induced pluripotent stem cells in cardiac tissue regeneration and engineering
Liu, Z., Zhou, J., Wang, H., Zhao, M., & Wang, C. (2013) · Regenerative Medicine Research · doi:10.1186/2050-490x-1-6 · Cited by 22
“MI: Myocardial infarction; iPSC: Induced pluripotent stem cell; ESC: Embryonic stem cell; EB: Embryoid body; CM: Cardiomyocyte; FD: Familial dysautonomia; SCNT: Somatic cell nuclear transfer; SMA: Spinal muscular atrophy; FACS: Fluorescence-activated cell sorting; LV: Left ventricle; Vc: Vitamin C.”
BackgroundReprogramming of COPD lung fibroblasts through formation of induced pluripotent stem cells
Basma, H., Gunji, Y., Iwasawa, S., Nelson, A. J., Farid, M., Ikari, J., Liu, X., Wang, X., Michalski, J., Smith, L. M., et al. (2014) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00255.2013 · Cited by 21
“Several studies have successfully generated iPSCs from a variety of tissues, including lung (36), and from patients with different diseases (3, 8, 13, 24).”
BackgroundMedicinal Biotechnology for Disease Modeling, Clinical Therapy, and Drug Discovery and Development
Duelen, R., Corvelyn, M., Tortorella, I., Leonardi, L., Chai, Y. C., & Sampaolesi, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-22141-6_5 · Cited by 29
Seranova, E., Palhegyi, A. M., Verma, S., Dimova, S., Lasry, R., Naama, M., Sun, C., Barrett, T. G., Rosenstock, T. R., Kumar, D., et al. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.01.024 · Cited by 23
Innovative approaches in CNS drug discovery
Charvériat, M., Lafon, V., Mouthon, F., & Zimmer, L. (2020) · Therapies · doi:10.1016/j.therap.2020.12.006 · Cited by 21
Animal modeling an oligodendrogliopathy – multiple system atrophy
Bleasel, J. M., Halliday, G. M., & Kim, W. S. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0279-6 · Cited by 19
“The first human iPSCs shown to model the specific pathology seen in a genetically inherited disease were derived from a child with spinal muscular atrophy [139].”
BackgroundInduced Pluripotency and Gene Editing in Disease Modelling: Perspectives and Challenges
Seah, S., Farran, C. A. E., Warrier, T., Xu, J., & Loh, Y. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226119 · Cited by 28
“In addition, disease models via iPSCs have been created for Alzheimer’s disease [96], amyotrophic lateral sclerosis (ALS) [97], spinal muscular atrophy (SMA) [98], Huntington’s disease [99], fragile X-syndrome [100] and childhood cerebral adrenoleukodystrophy (CCALD) [101] amongst others.”
BackgroundClinical Applications of Induced Pluripotent Stem Cells – Stato Attuale
Kavyasudha, C., Macrin, D., ArulJothi, K. N., Joseph, J. P., Harishankar, M. K., & Devi, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/5584_2018_173 · Cited by 20
Advances and applications of induced pluripotent stem cells
Pietronave, S., & Prat, M. (2012) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y11-125 · Cited by 19
“As an example, Ebert and colleagues generated iPS cells from a patient affected with spinal cord muscular atrophy (Ebert et al. 2009), and Lee et al. (2009) generated iPS cells from a patient affected with familial dysautonomia.”
BackgroundMyocardial regeneration of the failing heart
Akhmedov, A. T., & Marín-García, J. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9348-5 · Cited by 21
“Subsequently, this technique has been successfully applied to other cell types obtained from patients [74–77].”
MethodDevelopment and Regeneration of Projection Neuron Subtypes of the Cerebral Cortex
Tomassy, G. S., Lodato, S., Trayes-Gibson, Z., & Arlotta, P. (2010) · Science Progress · doi:10.3184/003685010x12705764469952 · Cited by 21
Induced Pluripotent Stem Cells and Their Use in Cardiac and Neural Regenerative Medicine
Skalová, Š., Švadláková, T., Qureshi, W. M. S., Dev, K., & Mokrý, J. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16024043 · Cited by 21
“culture periods as a result of reduced expression of SMN (survival motor neuron) protein [119].”
BackgroundChakraborty, S., Christoforou, N., Fattahi, A., Herzog, R. W., & Leong, K. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064342 · Cited by 22
“Reprogramming of somatic cells into a pluripotent-stem-cell-like state by retrovirus-based expression of Yamanaka transcription factors (Oct3/4, Sox2, Klf4 and c-Myc) have opened up new vistas in using lineage-specific cells for disease modeling, drug screening, developmental biology studies and cell-based therapies […”
BackgroundMartinez, Y., Dubois‐Dauphin, M., & Krause, K. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00047 · Cited by 20
“Motor neurons derived from SMA or FD patients hIPS exhibited, in vitro, morphological features of the disease (Ebert et al., 2009; Lee et al., FIGURE 1 | Generation of neural precursors or neural cells from pluripotent stem cells using differentiation or somatic cells using transdifferentiation.”
BackgroundMethodInfluentialTomov, M. L., Olmsted, Z. T., Dogan, H., Gongorurler, E., Tsompana, M., Otu, H. H., Buck, M. J., Chang, E.-A., Cibelli, J. B., & Paluh, J. L. (2016) · Scientific Reports · doi:10.1038/srep37637 · Cited by 21
Astrocytes in Motor Neuron Diseases
Valori, C. F., Guidotti, G., Brambilla, L., & Rossi, D. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-9913-8_10 · Cited by 22
Dhaulakhandi, D. B., Rohilla, S., & Rattan, K. N. (2010) · Fetal Diagnosis and Therapy · doi:10.1159/000318201 · Cited by 22
“Some recent examples include generation of spinal motor neurons and glia from a person suffering from amyotrophic lateral scelerosis, dopamine neurons derived from iPSCs derived from persons with Parkinson’s disease, motor neurons derived from iPSCs derived from a 3-year-old child with spinal muscular atrophy and deri…”
BackgroundAmniotic Fluid Stem Cells: A Novel Source for Modeling of Human Genetic Diseases
Antonucci, I., Provenzano, M., Rodrigues, M., Pantalone, A., Salini, V., Ballerini, P., Borlongan, C. V., & Stuppia, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040607 · Cited by 20
“The modeling of human genetic diseases by iPS cells allowed to test some specific drugs and to evaluate their efficiency on the derived cellular model, such as in the case of valproic acid and tobramycin in Spinal Muscular Atrophy [64], isoproterenol, cisapride and nifedipine in LQT syndrome [65], IGF1 and gentamicin…”
Backgroundla Vega, L. D., Karmirian, K., & Willerth, S. M. (2018) · Advanced Biosystems · doi:10.1002/adbi.201800133 · Cited by 19
Raković, A., Voß, D., Vulinović, F., Meier, B., Hellberg, A.-K., Nau, C., Klein, C., & Leipold, E. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.817198 · Cited by 21
“Human iPSCs are widely used to model physiological and pathophysiological conditions because they can be differentiated into a variety of cell types (Takahashi et al., 2007; Yu et al., 2007; Dimos et al., 2008; Ebert et al., 2009; Soldner et al., 2009; Guimaraes et al., 2018) including SNpc-associated DNs, which play…”
BackgroundEnhancing genome editing in hPSCs through dual inhibition of DNA damage response and repair pathways
Park, J.-C., Kim, Y.-J., Hwang, G., Kang, C. Y., Bae, S., & Cha, H. (2024) · Nature Communications · doi:10.1038/s41467-024-48111-9 · Cited by 21
“Since the advent of human induced pluripotent stem cells (iPSCs) 1 , patient-derived iPSCs harboring pathogenic mutations have been established for modeling disease phenotypes 2,3 .”
Nguyen, H. X., Nekanti, U., Haus, D. L., Funes, G., Moreno, D., Kamei, N., Cummings, B. J., & Anderson, A. J. (2014) · The Journal of Comparative Neurology · doi:10.1002/cne.23604 · Cited by 20
“Passage of neuralized spheres was designated as E, which a previous study referred to as “EZsphere” (Ebert et al., 2013).”
MethodResultLiu, J., Sümer, H., Leung, J., Upton, K. R., Dottori, M., Pébay, A., & Verma, P. J. (2011) · Cell Transplantation · doi:10.3727/096368910x514305 · Cited by 19
Stem cell-derived neurotrophic support for the neuromuscular junction in spinal muscular atrophy
Wyatt, T. J., & Keirstead, H. S. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.529895 · Cited by 22
“Recently, patient-specific induced pluripotent stem (iPS) cells have been generated from human adult somatic tissues [57-62] as well as from a variety of diseases including amyotrophic lateral sclerosis, muscular dystrophy and Huntington’s disease [57,63,64].”
BackgroundTracing the Conversion Process from Primordial Germ Cells to Pluripotent Stem Cells in Mice1
Nagamatsu, G., Kosaka, T., Saito, S., Takubo, K., Akiyama, H., Sudo, T., Horimoto, K., Oya, M., & Suda, T. (2012) · Biology of Reproduction · doi:10.1095/biolreprod.111.096792 · Cited by 20
“Several recent studies also report improved induction methods, including integration-free induction of reprogramming factors [3–9].”
BackgroundA review of Rett syndrome (RTT) with induced pluripotent stem cells
Vellingiri, B., Dhivya, V., Mohan, G., Mohanadevi, S., Venkatesh, B., & Geetha, B. (2016) · Stem Cell Investigation · doi:10.21037/sci.2016.09.05 · Cited by 20
“Indeed, hiPSC have been generated from a variety of diseases where specific phenotypes have been observed in vitro and proof-of-principle drug screens have been performed (3,29-32,142-145).”
BackgroundMethodReprogramming, oscillations and transdifferentiation in epigenetic landscapes
Kaity, B., Sarkar, R., Chakrabarti, B., & Mitra, M. K. (2018) · Scientific Reports · doi:10.1038/s41598-018-25556-9 · Cited by 20
Human iPSC Models to Study Orphan Diseases: Muscular Dystrophies
Xia, G., Terada, N., & Ashizawa, T. (2018) · Current Stem Cell Reports · doi:10.1007/s40778-018-0145-5 · Cited by 19
Modeling of psychiatric disorders using induced pluripotent stem cell-related technologies
Nakazawa, T., Hashimoto, R., Takuma, K., & Hashimoto, H. (2019) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2019.06.002 · Cited by 18
Kuo, Y., Shih-Huang, C.-Y., & Rajesh, R. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.111339 · Cited by 19
Zschüntzsch, J., Meyer, S., Shahriyari, M., Kummer, K., Schmidt, M., Kummer, S., & Tiburcy, M. (2022) · Cells · doi:10.3390/cells11071233 · Cited by 24
“This approach opens up the path toward the development of an isogenic human muscle-motoneuron platform which could provide the possibility of modulating neuromuscular diseases in a personalized manner [194,195].”
BackgroundSu, H., Wang, L., Cai, J., Yuan, Q., Yang, X., Yao, X., Wong, W., Huang, W., Li, Z., Wan, J., et al. (2013) · Stem Cell Research · doi:10.1016/j.scr.2013.02.007 · Cited by 19
Genome Engineering in Human Cells
Song, M., Kim, Y., Kim, J., & Kim, S. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-801185-0.00005-2 · Cited by 18
Human Induced Pluripotent Stem Cell and Nanotechnology-Based Therapeutics
Liu, W., Chang, Y.-L., Lo, W., Li, H.-Y., Hsiao, C., Peng, C.-H., Chiou, S., Ma, H.-I., & Chen, S. (2015) · Cell Transplantation · doi:10.3727/096368914x685113 · Cited by 19
Stem cell contributions to neurological disease modeling and personalized medicine
Liang, N., Trujillo, C. A., Negraes, P. D., Muotri, A. R., Lameu, C., & Ulrich, H. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.05.025 · Cited by 19
“The first study showing that human iPSC could be used to model and rescue a genetically AC CE PT ED M AN US CR IP T inherited disease was published in 2009 (Ebert et al. 2009), and the field has seen a rapidly growing number of published studies since then.”
SMN is required for the maintenance of embryonic stem cells and neuronal differentiation in mice
Chang, W.-F., Xu, J., Chang, C., Yang, S., Li, H.-Y., Hsieh‐Li, H. M., Tsai, M., Wu, S., Cheng, W. T.-K., Liu, J., et al. (2014) · Brain Structure and Function · doi:10.1007/s00429-014-0743-7 · Cited by 19
“Developmental delay and differentiation defects occurred at the end of differentiation in SMA mice, and similar results were shown in the SMNdepleted mouse embryonal carcinoma cell line as well as in iPSCs derived from an SMA patient (Trulzsch et al. 2007; Ebert et al. 2009).”
Illuminating the Potential of Pluripotent Stem Cells
Rosenzweig, A. (2010) · New England Journal of Medicine · doi:10.1056/nejme1007902 · Cited by 18
Stem Cells in Regenerative Medicine: A Journey from Adult Stem Cells to Induced Pluripotent Cells
Rocca, Y. D., Mazzone, A., Marconi, G. D., Trubiani, O., Pizzicannella, J., & Diomede, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178255 · Cited by 25
“This demonstrates that human iPSCs can be used to develop models of genetically inherited diseases, allowing the study of their pathophysiological mechanisms and the identification of new therapies [247].”
Two decades of induced pluripotent stem cell research: From discovery to diverse applications
Yamanaka, S. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.02.003 · Cited by 21
Cellular reprogramming: a novel tool for investigating autism spectrum disorders
Kim, K., Jung, Y. W., Sullivan, G. J., Chung, L., & Park, I. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.06.002 · Cited by 18
“Thus far, when iPSCs are used in cellular models, iPSCs from healthy persons have been used as controls for most disease models [21].”
MethodKalra, R. S., Dhanjal, J. K., Das, M., Singh, B., & Naithani, R. (2021) · Cells · doi:10.3390/cells10102558 · Cited by 21
Park, J.-C., Kim, Y.-J., Han, J. H., Kim, D., Park, M. J., Kim, J., Jang, H., Bae, S., & Cha, H. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.015 · Cited by 18
Optogenetic and chemogenetic approaches for modeling neurological disorders in vivo
Krut’, V. G., Kalinichenko, A. L., Maltsev, D. I., Jappy, D., Shevchenko, E. K., Podgorny, O. V., & Belousov, V. V. (2024) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2024.102600 · Cited by 20
Cicero, A. L., & Nissan, X. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.10.002 · Cited by 17
The Promise of Human Induced Pluripotent Stem Cells in Dental Research
Srijaya, T. C., Pradeep, P. J., Zain, R. B., Musa, S., Kasim, N. H. A., & Govindasamy, V. (2012) · Stem Cells International · doi:10.1155/2012/423868 · Cited by 20
“Moreover, these iPSC lines were able to differentiate into required cell types of relevant diseases and recapitulate disease-specific effects in vitro which may not be detectable in animal models [31, 32].”
BackgroundStem cells and the ALS neurologist
Maragakis, N. J. (2010) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482968.2010.489116 · Cited by 19
Current advances in drug development in spinal muscular atrophy
Singh, P., Liew, W. K. M., & Darras, B. T. (2013) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32836565ac · Cited by 17
“com Cell replacement therapy Recent preclinical studies involving pluripotent stem cells have shown promise as a potential treatment for SMA and as a useful tool in constructing model systems for therapeutic development [57,58].”
MethodReprogramming of Human Huntington Fibroblasts Using mRNA
Arnold, A., Naaldijk, Y., Fabian, C., Loeffler‐Wirth, H., Binder, H., Nikkhah, G., Armstrong, L., & Stolzing, A. (2011) · ISRN Cell Biology · doi:10.5402/2012/124878 · Cited by 18
Nanomedicine-Based Neuroprotective Strategies in Patient Specific-iPSC and Personalized Medicine
Jang, S.-F., Liu, W., Song, W.-S., Chiang, K.-L., Ma, H.-I., Kao, C.-L., & Chen, M.-T. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15033904 · Cited by 17
“For example, patient-specific iPSCs have been differentiated into neural crest precursors, motor neurons, and mature hepatocytes [97].”
BackgroundThe translational potential of human induced pluripotent stem cells for clinical neurology
Devine, H. E., & Patani, R. (2016) · Cell Biology and Toxicology · doi:10.1007/s10565-016-9372-7 · Cited by 19
Ochałek, A., Szczęsna, K., Petazzi, P., Kobolák, J., & Dinnyés, A. (2016) · Stem Cells International · doi:10.1155/2016/5838934 · Cited by 18
“production Motor neurons (i) iPSCs with SMN1 mutation from SMA type I patients [64, 65]”
Modeling neuronopathic storage diseases with patient-derived culture systems
Zunke, F., & Mazzulli, J. R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.01.018 · Cited by 17
Hawkins, K., & Duchen, M. R. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i5.236 · Cited by 18
Hyperexcitability precedes motoneuron loss in the Smn 2B/− mouse model of spinal muscular atrophy
Quinlan, K. A., Reedich, E. J., Arnold, W. D., Puritz, A., Cavarsan, C. F., Heckman, C. J., & DiDonato, C. J. (2019) · Journal of Neurophysiology · doi:10.1152/jn.00652.2018 · Cited by 21
Spinal Muscular Atrophy Modeling and Treatment Advances by Induced Pluripotent Stem Cells Studies
Adami, R., & Bottai, D. (2019) · Stem Cell Reviews and Reports · doi:10.1007/s12015-019-09910-6 · Cited by 19
“SMA1 Fibroblast cell lines Motor Neurons, Neurons, Astrocytes Cell number andmorphology at long time point, nuclear gems lack VPA and tobramycin treatment increase nuclear gems number First report validating SMA iPSCs modeling [116]”
BackgroundUsing MS induced pluripotent stem cells to investigate MS aetiology
Fortune, A. J., Fletcher, J. L., Blackburn, N. B., & Young, K. M. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103839 · Cited by 17
Mokry, R. L., O’Brien, B. S., Adelman, J. W., Rosas-Rogers, S., Schumacher, M. L., Ebert, A. D., & Terhune, S. S. (2022) · Journal of Virology · doi:10.1128/jvi.00126-22 · Cited by 20
“Undifferentiated induced pluripotent stem cell (iPSC) colonies, initially derived from fibroblasts (Coriell fibroblast line GM003814) (52, 53), from a healthy individual were maintained in Essential 8 medium (Thermo Fisher Scientific) and grown under feeder-free conditions on Matrigel (Corning).”
MethodSelf-citationInduced pluripotent stem cells – alchemist's tale or clinical reality?
Rashid, S. T., & Vallier, L. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399410001596 · Cited by 18
Induced pluripotent stem cells free of exogenous reprogramming factors
Abujarour, R., & Ding, S. (2009) · Genome biology · doi:10.1186/gb-2009-10-5-220 · Cited by 18
“As a proof of concept, disease-specific iPSCs have been generated [12-14], and have been used to model disease [14]”
Stem cell‐derived astrocytes: are they physiologically credible?
Hill, E. J., Nagel, D. A., Parri, H. R., & Coleman, M. D. (2016) · The Journal of Physiology · doi:10.1113/jp270658 · Cited by 20
“2009), spinal muscular atrophy (Ebert et al. 2009), Rett syndrome (Marchetto et al.”
BackgroundDrug screening with human SMN2 reporter identifies SMN protein stabilizers to correct SMA pathology
Wang, Y., Xu, C., Ma, L., Mou, Y., Zhang, B., Zhou, S., Tian, Y., Trinh, J., Zhang, X., & Li, X.-J. (2019) · Life Science Alliance · doi:10.26508/lsa.201800268 · Cited by 18
“(Ebert et al., 2009; Heier and DiDonato, 2009; Wolstencroft et al., 2005) 4 GSK-3 inhibitor SMN is phosphorylated by GSK-3 and degraded much more rapid.”
BackgroundEngineering microsystems to recapitulate brain physiology on a chip
Ndyabawe, K., & Kisaalita, W. S. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.008 · Cited by 18
The CARM1 transcriptome and arginine methylproteome mediate skeletal muscle integrative biology
vanLieshout, T. L., Stouth, D. W., Hartel, N. G., Vasam, G., Ng, S. Y., Webb, E. K., Rebalka, I. A., Mikhail, A. I., Graham, N. A., Menzies, K. J., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101555 · Cited by 17
Concise Review: Patient-Derived Stem Cell Research for Monogenic Disorders
Qin, Y., & Gao, W. (2015) · Stem Cells · doi:10.1002/stem.2112 · Cited by 17
The genomic stability of induced pluripotent stem cells
Chen, Z., Zhao, T., & Xu, Y. (2012) · Protein & Cell · doi:10.1007/s13238-012-2922-8 · Cited by 18
“In this context, iPSC technology has been used to model a large panel of human diseases including spinal muscular atrophy (Ebert et al., 2009), amyotrophic lateral sclerosis (Dimos et al.”
MethodChoreographing pluripotency and cell fate with transcription factors
Gonzales, K. A. U., & Ng, H. (2011) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2011.06.009 · Cited by 17
Wang, Y., Umeda, K., & Nakayama, N. (2010) · Stem Cell Research · doi:10.1016/j.scr.2010.03.002 · Cited by 16
“Such technical improvements have opened a path toward clinically relevant, patient-specific pluripotent stem cells for personalized regenerative medicine based on iPS cells (Dimos et al., 2008; Ebert et al., 2009; Soldner et al., 2009).”
BackgroundA Step Closer to Complete Chemical Reprogramming for Generating iPS Cells
Solanki, A., & Lee, K. (2010) · ChemBioChem · doi:10.1002/cbic.201000032 · Cited by 18
Stabley, D. L., Holbrook, J., Harris, A. W., Swoboda, K. J., Crawford, T. O., Sol‐Church, K., & Butchbach, M. E. R. (2017) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.02.002 · Cited by 20
“Unfortunately, this cell line has been mislabeled as a type I SMA fibroblast in 254 the vendor’s database and this incorrect identification has been reflected in multiple studies, 255 including [23;43].”
Schork, N. J., & Nazor, K. L. (2017) · Advances in genetics · doi:10.1016/bs.adgen.2017.06.001 · Cited by 21
Sneha, P., Zenith, T. U., Habib, U. S. A., Judith, E., Kumar, D. T., Doss, C. G. P., Ramamoorthy, S., & Zayed, H. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0285-4 · Cited by 17
Son, Y. S., Choi, K., Lee, H., Kwon, O., Jung, K. B., Cho, S., Baek, J., Son, B., Kang, S., Kang, M.-G., et al. (2019) · Stem Cells and Development · doi:10.1089/scd.2018.0181 · Cited by 17
“Analysis of SMA patient-specific iPSCs (SMA iPSCs) has revealed varying degrees of MN loss, consistent with a neurodegenerative status particularly in MNs [17–19].”
Selective serotonin reuptake inhibitors ameliorate MEGF10 myopathy
Saha, M., Rizzo, S. A., Ramanathan, M., Hightower, R. M., Santostefano, K. E., Terada, N., Finkel, R. S., Berg, J. S., Chahin, N., Pacak, C. A., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz064 · Cited by 17
“iPSCs derived from human tissue samples (33,34) serve as valuable models of human disease (35,36), especially when differentiated into relevant cell lines (37,38).”
BackgroundFaye, P.-A., Védrenne, N., Miressi, F., Rassat, M., Romanenko, S., Richard, L., Bourthoumieu, S., Funalot, B., Sturtz, F. G., Favreau, F. D., et al. (2020) · Brain Sciences · doi:10.3390/brainsci10070407 · Cited by 19
Modeling Type 1 Diabetes Using Pluripotent Stem Cell Technology
Joshi, K., Cameron, F. J., Tiwari, S., Mannering, S. I., Elefanty, A. G., & Stanley, E. G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.635662 · Cited by 18
Stem Cell Models and Gene Targeting for Human Motor Neuron Diseases
Karpe, Y., Chen, Z.-Y., & Li, X.-J. (2021) · Pharmaceuticals · doi:10.3390/ph14060565 · Cited by 17
“Patient-specific iPSCs were established by reprogramming fibroblasts from a 3-year-old boy suffering from SMA type I patient via lentiviral transduction in 2009 [97].”
MethodNuclear receptors in stem cells and their therapeutic potential
Sun, G., & Shi, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.08.003 · Cited by 18
“Patient-specific iPSCs were also generated from skin fibroblasts of spinal muscular atrophy patients using a reprogramming cocktail (Oct4, Sox2 Nanog, and Lin28) [67].”
Using human pluripotent stem cells to untangle neurodegenerative disease mechanisms
Malgrange, B., Borgs, L., Grobarczyk, B., Purnelle, A., Ernst, P., Moonen, G., & Nguyen, L. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0557-6 · Cited by 17
“Indeed, hiPS derived from SMA patients initially produce the same number of motor neurons as compared to control hips in culture, but the disease phenotype selectively impedes motor neuron production or increases their degeneration at later time points.”
InfluentialGeneration of familial amyloidotic polyneuropathy-specific induced pluripotent stem cells
Isono, K., Jono, H., Ohya, Y., Shiraki, N., Yamazoe, T., Sugasaki, A., Era, T., Fusaki, N., Tasaki, M., Ueda, M., et al. (2014) · Stem Cell Research · doi:10.1016/j.scr.2014.01.004 · Cited by 17
Specification of functional neurons and glia from human pluripotent stem cells
Jiang, Y., Zhang, M., & Hu, B. (2012) · Protein & Cell · doi:10.1007/s13238-012-2086-6 · Cited by 17
Kuwabara, T., & Asashima, M. (2012) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjs016 · Cited by 18
Pluripotency of Induced Pluripotent Stem Cells
Kang, L., & Gao, S. (2012) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/2049-1891-3-5 · Cited by 20
“The generation of iPS cells from individual patients has raised the hope of treatments for numerous degenerative and genetic diseases [4-11].”
Guided differentiation and tissue regeneration of induced pluripotent stem cells using biomaterials
Kuo, Y., & Rajesh, R. (2017) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2017.04.043 · Cited by 16
Dowaidar, M. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/3nwzd · Cited by 26
Timofeeva, A. M., Aulova, K. S., & Nevinsky, G. A. (2025) · Brain Sciences · doi:10.3390/brainsci15050486 · Cited by 17
“These disorders include Parkinson’s disease [251–253], amyotrophic lateral sclerosis [254–256], smooth muscle atrophy [257,258], familial dysautonomia [259], Rett syndrome [260], schizophrenia [261], and others.”
Induced pluripotent stem cells for spinal cord injury therapy: current status and perspective
Wang, H., Fang, H., Dai, J., Liu, G., & Xu, Z. (2012) · Neurological Sciences · doi:10.1007/s10072-012-1145-3 · Cited by 19
“[44] reprogramed the fibroblasts of a child with spinal muscular atrophy into iPSCs and found that neural cells differentiated from these iPSCs exhibited the genotypes and phenotypes of spinal muscular atrophy, suggesting that IPSCs have broad application in disease modeling and drug screening.”
BackgroundThe Janus face of pluripotent stem cells – Connection between pluripotency and tumourigenicity
Wobus, A. M. (2010) · BioEssays · doi:10.1002/bies.201000065 · Cited by 19
Functional evaluation of genetic variation in complex human traits
Peters, D. T., & Musunuru, K. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds363 · Cited by 15
Li, D., Johmura, Y., Morimoto, S., Doi, M., Nakanishi, K., Ozawa, M., Tsunekawa, Y., Inoue‐Yamauchi, A., Naruse, H., Matsukawa, T., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00464-4 · Cited by 17
Stem Cell Based Strategies for Spinal Cord Injury Repair
Reeves, A. L., & Keirstead, H. S. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-4090-1_2 · Cited by 16
Biomedical and Clinical Promises of Human Pluripotent Stem Cells for Neurological Disorders
Jongkamonwiwat, N., & Noisa, P. (2013) · BioMed Research International · doi:10.1155/2013/656531 · Cited by 17
“For example, MNs derived from hiPSCs, which were obtained from an SMA patient, exhibited shortened neurite extensions and diminished survival in culture compared to healthyMNs [89].”
Epigenetic modulations of induced pluripotent stem cells: novel therapies and disease models
Huang, C., & Wu, J. C. (2012) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2012.02.004 · Cited by 17
Crook, J. M., Wallace, G. G., & Tomaskovic‐Crook, E. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1013096 · Cited by 19
Stem Cells in Skeletal Tissue Engineering: Technologies and Models
Langhans, M. T., Yu, S., & Tuan, R. S. (2015) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x10666151001115248 · Cited by 17
Differentiation of White and Brown Adipocytes from Human Pluripotent Stem Cells
Lee, Y., & Cowan, C. A. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-800280-3.00003-7 · Cited by 15
Metadata
- Authors
- Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N.
- Affiliations
- University of Wisconsin–Madison (US)
- University of Missouri (US)
- Corresponding author
- Ebert, Allison D.
- Svendsen, Clive N.
- Venue
- Nature
- Published
- 2008-12-21
- Volume
- 457
- Issue
- 7227
- Pages
- 277-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2659408
- OpenAlex
- W2145492799
- Cited by
- 1,441
- References
- 42
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 28 · 2023: 31 · 2022: 36 · 2021: 33 · 2020: 46 · 2019: 54 · 2018: 53 · 2017: 60 · 2016: 85 · 2015: 109 · 2014: 112 · 2013: 145 · 2012: 199
- FWCI
- 58.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute on Aging (T32AG027566)
- National Institute of General Medical Sciences (T32GM008396)
- National Institute of Neurological Disorders and Stroke (R01 NS41584, P01NS057778, R01NS041584)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD054413)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- spinal muscular atrophy, induced pluripotent stem cells, motor neurons, SMN1, SMN2, dermal fibroblasts, disease modeling, neural progenitor cells, drug screening, inherited neurological diseases, Huntington's disease
- MeSH terms
- Cell Differentiation, Cell Separation, Cells, Cultured, Child, Female, Fibroblasts, Gene Expression Regulation, Humans, Male, Models, Biological, Motor Neurons, Muscular Atrophy, Spinal, Skin, Cell Lineage, Pluripotent Stem Cells, Survival of Motor Neuron 1 Protein, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.